SCHEMBL4027465

SCHEMBL4027465

CC(C)c1ccc(C(=O)OCCCCN2CCC(OCc3ccccc3)CC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
BCHE P06276 19/20 1.00
TMEM97 Q5BJF2 1/20 0.48
CARM1 Q86X55 1/20 0.48
PRMT6 Q96LA8 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
PRMT8 Q9NR22 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4028855 0.90 BCHE (1.00) BCHETMEM97CARM1PRMT6SIGMAR1
SCHEMBL4020282 0.89 BCHE (1.00) BCHE
SCHEMBL4026157 0.87 BCHE (1.00) BCHE
SCHEMBL4031121 0.86 BCHE (1.00) BCHETMEM97CARM1PRMT6SIGMAR1
SCHEMBL4029519 0.85 BCHE (1.00) BCHE
SCHEMBL4025407 0.83 BCHE (1.00) BCHETMEM97
SCHEMBL4024650 0.82 BCHE (1.00) BCHECARM1PRMT6HRH3
SCHEMBL4027386 0.80 BCHE (1.00) BCHECARM1PRMT6PRMT8
SCHEMBL4020320 0.80 BCHE (0.66) BCHETMEM97CARM1PRMT6SIGMAR1
SCHEMBL13963921 0.76 BCHE (1.00) BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1446400-B1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO LTD (KR) 2009-01-28 EP disclosed
EP-1446400-B1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO LTD (KR) 2009-01-28 EP disclosed
US-7288552-B2 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same STC NARA CO., LTD. (KR) 2007-10-30 US disclosed
US-7288552-B2 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same STC NARA CO., LTD. (KR) 2007-10-30 US disclosed
US-7288552-B2 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same STC NARA CO., LTD. (KR) 2007-10-30 US disclosed
EP-1446400-A4 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO LTD (KR) 2005-06-01 EP disclosed
US-20050043316-A1 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same STC NARA CO., LTD. (KR) 2005-02-24 US disclosed
EP-1446400-A1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC Nara Co. Ltd. (KR) 2004-08-18 EP disclosed
WO-2003033489-A1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO., LTD. (KR) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043316-A1 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same APP, ACHE, PSEN1 BCHE 7/4885TMEM97 1837/4885CARM1 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.